Selective targeting of radiation-resistant tumor-initiating cells.
Tumor-initiating cells (TICs) have been shown both experimentally and clinically to be resistant to radiation and chemotherapy, potentially resulting in residual disease that can lead to recurrence. In this study, we demonstrate that TICs isolated from p53 null mouse mammary tumors repair DNA damage following in vivo ionizing radiation more efficiently than the bulk of the tumor cells. Down-regulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was observed both in fluorescence activated cell sorting (FACS)-isolated TICs as compared to non-TICs and in TIC-enriched mammospheres as compared to primary tumor cells depleted of TICs. This effect was accompanied by increased Akt signaling, as well as by the direct activation of the canonical Wnt/beta-catenin signaling pathway specifically within the TIC subpopulation by phosphorylation of beta-catenin on serine 552. Using limiting dilution transplantation performed on p53 null tumor cells transduced with Wnt reporter lentivirus, we demonstrated that FACS sorting of cells expressing TOP-eGFP resulted in a marked enrichment for TICs. Furthermore, FACS analysis demonstrated that cells with active Wnt signaling overlapped with the TIC subpopulation characterized previously using cell surface markers. Finally, pharmacological inhibition of the Akt pathway in both mammospheres and syngeneic mice bearing tumors was shown to inhibit canonical Wnt signaling as well as the repair of DNA damage selectively in TICs, sensitizing them to ionizing radiation treatment. Thus, these results suggest that pretreatment with Akt inhibitors before ionizing radiation treatment may be of potential therapeutic benefit to patients.
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030-3498, USA.
Mei
M
Zhang
Rachel L
RL
Atkinson
Jeffrey M
JM
Rosen
D000818:Animals; D002469:Cell Separation; D004249:DNA Damage; D004260:DNA Repair / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008817:Mice, Mutant Strains; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000201:enzymology* / Q000528:radiation effects*; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D011836:Radiation Tolerance; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D051153:Wnt Proteins / Q000378:metabolism
D047428:Protein Kinase Inhibitors; D016159:Tumor Suppressor Protein p53; D051153:Wnt Proteins; D010767:Phosphorylcholine; C105905:perifosine; D051057:Proto-Oncogene Proteins c-akt